Adrenomedullin (1-12), human

Adrenomedullin (1-12), human

Catalog Number:
CR04368103APE
Mfr. No.:
APE-A1001
Price:
$172
  • Size:
    Quantity:
    Add to Cart:
      • Overview
        • Please contact us at for specific academic pricing.

          Background

          Adrenomedullin (AM) (1-12), human (C64H100N22O19S1), is a peptide with the sequence Tyr-Arg-Gln-Ser-Met-Asn-Asn-Phe-Gln-Gly-Leu-Arg. It was first discovered to be associated with pheochromocytoma, a tumor arising from adrenal medulla, in 1993. AM was initially identified as a vasodilator, and as such, it has the ability to relax vascular tone. Previous research cited it as the most potent endogenous vasodilatory peptide found in the body. Other effects of AM include the increase of cell tolerance to oxidative stress and hypoxic injury and angiogenesis. AM is seen as a positive influence in diseases such as hypertension, myocardial infarction, chronic obstructive pulmonary disease and other cardiovascular conditions.

      • Properties
        • Categories
          Vasodilator
          Alternative Name
          H2N-Tyr-Arg-Gln-Ser-Met-Asn-Asn-Phe-Gln-Gly-Leu-Arg-OH
          Molecular Formula
          C64H100N22O19S
          Molecular Weight
          1513.68
          Appearance
          A solid
          Purity
          98.99%
          Solubility
          insoluble in EtOH; ≥151.3 mg/mL in DMSO; ≥4.86 mg/mL in H2O
          Storage
          Store at -20°C
          SMILES
          N[[email protected]@H](CC1=CC=C(O)C=C1)C(N[[email protected]@H](CCCNC(N)=N)C(N[[email protected]@H](CCC(N)=O)C(N[[email protected]@H](CO)C(N[[email protected]@H](CCSC)C(N[[email protected]@H](CC(N)=O)C(N[[email protected]@H](CC(N)=O)C(N[[email protected]@H](CC2=CC=CC=C2)C(N[[email protected]@H](CCC(N)=O)C(NCC(N[[email protected]@H](CC(C)C)C(N[[email protected]@H](CCCNC(N)=N)C(O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O

          * For Research Use Only

    Note: If you don't receive our verification email, do the following:

  • Copyright © Amerigo Scientific. All rights reserved.